RevMed's Cancer Pill Shows 60% Death Risk Reduction
RAS mutations drive 90% of pancreatic cancer cases.
Patients lived 13.2 months vs 6.7 months on chemo.
CEO called results 'dramatic, practice-changing outcomes.'. Company plans FDA approval via National Priority Voucher.
Shares rose 30% after announcement.
Trial targets newly diagnosed patients.
4 days ago